Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.58 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1552540 | 1.00 | HTR1A (0.58) | HTR1AGRIN1GRIN2BHDAC1HDAC8 | |
| SCHEMBL1551857 | 1.00 | HTR1A (0.58) | HTR1AGRIN1GRIN2BHDAC1HDAC8 | |
| SCHEMBL1552656 | 0.82 | SLC6A2 (0.47) | HTR1ASLC6A2SLC6A4 | |
| SCHEMBL31749404 | 0.81 | HTR1A (0.42) | HTR1AGRIN1GRIN2BSLC6A2SLC6A4 | |
| SCHEMBL30450901 | 0.79 | TAAR1 (0.50) | — | |
| SCHEMBL1552428 | 0.79 | SLC6A2 (0.44) | HTR1ASLC6A2SLC6A4 | |
| SCHEMBL1552434 | 0.79 | HTR2B (0.41) | HTR1ASLC6A2SLC6A4 | |
| SCHEMBL1552432 | 0.79 | HTR2B (0.41) | HTR1ASLC6A2SLC6A4 | |
| SCHEMBL1551817 | 0.79 | DRD2 (0.41) | HTR1ASLC6A2SLC6A4 | |
| SCHEMBL1551814 | 0.79 | DRD2 (0.41) | HTR1ASLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1844026-B1 | MORPHOLINES AS 5HT2C AGONISTS | HOFFMANN LA ROCHE (CH) | 2011-04-27 | — | — | EP | claimed |
| CN-101107235-B | Morpholines as 5HT2C agonists | HOFFMANN LA ROCHE | 2011-03-16 | — | — | CN | claimed |
| US-7323466-B2 | Morpholine derivatives as 5HT2C receptor agonists for the treatment of obesity | HOFFMAN-LA ROCHE INC. (US) | 2008-01-29 | — | — | US | claimed |
| CN-101107235-A | Morpholines as 5HT2C agonists | HOFFMANN LA ROCHE (CH) | 2008-01-16 | — | — | CN | claimed |
| EP-1844026-A2 | MORPHOLINES AS 5HT2C AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-10-17 | — | — | EP | claimed |
| US-20060178510-A1 | New morpholine derivatives as 5HT2C receptor agonists for the treatment of obesity | HOFFMANN-LA ROCHE INC. | 2006-08-10 | — | — | US | claimed |
| WO-2006077025-A2 | MORPHOLINES AS 5HT2C AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-27 | — | — | WO | claimed |
| US-20130005710-A1 | AMINOPYRIDINE DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-03 | — | — | US | disclosed |
| EP-2502909-A1 | AMINOPYRIDINE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2012-09-26 | — | — | EP | disclosed |
| EP-1844026-B1 | MORPHOLINES AS 5HT2C AGONISTS | HOFFMANN LA ROCHE (CH) | 2011-04-27 | — | — | EP | disclosed |
| CN-101107235-B | Morpholines as 5HT2C agonists | HOFFMANN LA ROCHE | 2011-03-16 | — | — | CN | disclosed |
| US-7323466-B2 | Morpholine derivatives as 5HT2C receptor agonists for the treatment of obesity | HOFFMAN-LA ROCHE INC. (US) | 2008-01-29 | — | — | US | disclosed |
| CN-101107235-A | Morpholines as 5HT2C agonists | HOFFMANN LA ROCHE (CH) | 2008-01-16 | — | — | CN | disclosed |
| EP-1844026-A2 | MORPHOLINES AS 5HT2C AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-10-17 | — | — | EP | disclosed |
| US-20060178510-A1 | New morpholine derivatives as 5HT2C receptor agonists for the treatment of obesity | HOFFMANN-LA ROCHE INC. | 2006-08-10 | — | — | US | disclosed |
| WO-2006077025-A2 | MORPHOLINES AS 5HT2C AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005710-A1 | AMINOPYRIDINE DERIVATIVE | DCX, NR0B1, NR4A1 | HTR1A 249/4885GRIN1 44/4885GRIN2B 85/4885 |
| US-20060178510-A1 | New morpholine derivatives as 5HT2C receptor agonists for the treatment of obesity | HTR2C, HTR1A, HTR1B | HTR1A 2/4885GRIN1 319/4885GRIN2B 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.